Gemfibrozil-induced decrease in serum ubiquinone and α- and γ- tocopherol levels in men with combined hyperlipidaemia

European Journal of Clinical Investigation

Volumn 28, Issue 3, 1998, Pages 235-242

  Aberg F ^a   Appelkvist, E L ^a,c   Broijersen A ^b   Eriksson, M ^b   Angelin, B ^b   Hjemdahl, P ^b   Dallner, G ^a  

^a Clinical Research Center   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Clinical Research Center   (Sweden)

Author keywords

tocopherol; Gemfibrozil; Hyperlipidaemia; Ubiquinone; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; GAMMA TOCOPHEROL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UBIQUINONE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG SCREENING; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; VITAMIN BLOOD LEVEL;

ADULT; AGED; ANTILIPEMIC AGENTS; ANTIOXIDANTS; APOLIPOPROTEINS; CASE-CONTROL STUDIES; CORONARY DISEASE; CROSS-OVER STUDIES; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEINS; MALE; MIDDLE AGED; UBIQUINONE; VITAMIN E;

EID: 0031982317     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00262.x     Document Type: Article

References (46)

1. Tribble DL, van den Berg JJM, Motchnik PA, et al. Oxidative susceptibility of low density lipoprotein subfractions is related to their ubiquinol-10 and α-tocopherol content. Proc Natl Acad Sci USA 1994; 91: 1183-7.
2. Stocker R, Bowry VW, Frei B. Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does α-tocopherol. Proc Natl Acad Sci USA 1991; 88: 1646-50.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989; 320: 915-24.
4. Gey KF, Puska P, Jordan P, Moser UK. Inverse correlation between plasma vitamin E and mortality from ischemic heart disease in cross-cultural epidemiology. Am J Clin Nutr 1991; 53: 326S-34S.
5. Riemersma RA, Wood DA, MacInryre CCH, Elton RA, Gey KF, Oliver MF. Risk of angina pectoris and plasma concentrations of vitamins A, C, E and carotene. Lancet 1991; 337: 1-5.
6. Knekt P, Reunanen A, Järvinen R, Seppänen R, Heliövaara M, Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol 1994; 139: 1180-9.
7. Rimm EB, Stampfer MJ, Acsherio A, Giovannucci E, Colditz GA, Willett WC. Vitamin E consumption and the risk of coronary heart disease in men. N Engl J Med 1993; 328: 1450-6.
8. Stampfer MJ, Hennekens CH, Manson JE, Colditz GA, Rosner BSB, Willett WC, Vitamin E consumption and the risk of coronary disease in women. N Engl J Med 1993; 328: 1444-9.
9. Ernster L, Beyer RE. Antioxidant functions of coenzyme Q; some biochemical and pathophysiological implications. In: Folkers K, Littarru G, Yamagami T, eds. Biomedical and Clinical Aspects of Coenzyme Q, Vol. 6. Amsterdam: Elsevier 1991: 45-58.
10. Brunzell JD, Schrott HG, Motulsky AG, Bierman EL. Myocardial infarction in the familial forms of hypertriglyceridemia. Metabolism 1976; 25: 313-20.
11. Grundy SM, Chait A, Brunzell JD. Familial combined hyperlipidaemia workshop. Atherosclerosis 1987; 7: 203-7.
12. Yang CY, Gu ZW, Xie YH et al. Effects of gemfibrozil on very-low-density lipoprotein composition and low-density lipoprotein size in patients with hypertriglyceridemia or combined hyperlipidaemia. Atherosclerosis 1996; 126: 105-16.
13. Tsai MY, Yuan J, Hunninghake DB. Effect of gemfibrozil on composition of lipoproteins and distribution of LDL subspecies. Atherosclerosis 1992; 95: 35-42.
14. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PNM, Hendriks JCM, Stalenhoef AFH. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11: 298-306.
15. Bjørneboe A, Bjørneboe G-E, Drevon CA. Absorption, transport and distribution of vitamin E. J Nutr 1990; 120: 233-42.
16. Elmberger PG, Kalén A, Brunk U, Dallner G. Discharge of newly synthesized dolichol, dolichyl phosphate and ubiquinone with lipoproteins to rat liver perfusate and to the bile. Lipids 1989; 24: 919-30.
17. Elmberger PG, Kalén A, Lund E, et al. Effects of pravastatin and cholesryramine on products of the mevalonate pathway in familial hypercholesterolemia. J Lipid Res 1991; 32: 35-40.
18. Folkers K, Langsjoen P, Willis R et al. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990; 87: 8931-4.
19. Ghirlanda G, Oradei A, Manto A et al. Evidence of plasma CoQ-10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993; 33: 226-9.
20. Bredie SJH, de Bruin TWA, Demacker PNM, Kastelein JJP, Stalenhoef AFH. Comparison of gemfibrozil vs. simvastatin in familial combined hyperlipidaemia and effects on apolipoprotein-B-containing lipoproteins, profile, and low-density lipoprotein oxidizability. Am J Cardiol 1995; 75: 348-53.
21. Bröijersén A, Eriksson M, Angelin B, Hjemdahl P. Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia. Arterioscler Thromb Vasc Biol 1995; 15: 121-7.
22. Bröijersén A, Eriksson M, Wiman B, Angelin B, Hjemdahl P. Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. Arterioscler Thromb Vasc Biol 1996; 16: 511-6.
23. Bröijersén A, Hamsten A, Silveira A et al. Gemfibrozil reduces thrombin generation in patients with combined hyperlipidaemia without influencing plasma fibrinogen, fibrin gel structure or coagulation factor VII. Thromb Haemost 1996; 76: 171-6.
24. Ericsson J, Appelkvist EL, Thelin A, Chojnacki T, Dallner G. Isoprenoid biosynthesis in rat liver peroxisomes. Characterization of cis-prenyltransferase and squalene synthase. J Biol Chem 1992; 267: 18708-14.
25. Zhang Y, Turunen M, Appelkvist EL. Restricted uptake of dietary coenzyme Q is in contrast to the unrestricted uptake of α-tocopherol into rat organs and cells. J Nutr 1996; 126: 2089-97.
26. Carlson K. Lipoprotein fractionation. J Clin Pathol 1973; 26 (Suppl. 5): 32-7.
27. Lopes-Virella MF, Stone P, Ellis S, Colwell JA. Cholesterol determination in high density lipoprotein separated by three different methods. Clin Chem 1977; 23: 882-4.
28. Jones B, Kenward MG. Design and analysis of cross-over trials. New York: Chapman & Hall 1989.
29. Jialal I, Grundy SM. Effect of dietary supplementation with alpha-tocopherol on the oxidative modification of low-density lipoprotein. J Lipid Res 1992; 33: 899-906.
30. Tikkanen MJ. Fibric acid derivatives. Curr Opin Lipidol 1992; 3: 29-33.
31. Zhang Y, Åberg F, Appelkvist EL, Dallner G, Ernster L. The uptake of dietary coenzyme Q supplement is limited in rats. J Nutr 1995; 125: 446-53.
32. Andersson M, Ericsson J, Appelkvist EL, Schedin S, Chojnacki T, Dallner G. Modulations in hepatic branch-point enzymes involved in isoprenoid biosynthesis upon dietary and drug treatments of rats. Biochim Biophys Acta 1994; 1214: 79-87.
33. Åberg F, Zhang Y, Teclebrhan H, Appelkvist EL, Dallner G. Increases in tissue levels of ubiquinone in association with peroxisome proliferation. Chem-Biol Interact 1996; 99: 205-18.
34. Hashimoto F, Hamada S, Hayashi H. Effect of gemfibrozil on centrifugal behavior of rat peroxisomes and activities of peroxisomal enzymes involved in lipid metabolism. Biol Pharm Bull 1997; 20: 315-21.
35. Teclebrhan H, Olsson J, Swiezewska E, Dallner G. Biosynthesis of the side chain of ubiquinone: trans-prenyltransferase in rat liver microsomes. J Biol Chem 1993; 268: 23081-6.
36. Kayden HJ, Traber MG. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J Lipid Res 1993; 34: 343-58.
37. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 1996; 37: 907-25.
38. Riemersma RA, Oliver M, Elton RA et al. Plasma antioxidants and coronary heart disease: vitamin C and E, and selenium. Eur J Clin Nutr 1990; 44: 143-50.
39. Stephens NG, Parsons A, Schofield PM et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347: 781-6.
40. 2. Arterioscler Thromb Vasc Biol 1995; 15: 1131-8.
41. Naseem KM, Goodall AH, Bruckdorfer KR. The extent of oxidative modification of LDLs is critical in determining their effects on platelet function. Atherosclerosis 1994; 109; abstract 148.
42. Calzada C, Bruckdorfer KR, Rice-Evans CA. The influence of antioxidant nutrients on platelet function in healthy volunteers. Atherosclerosis 1997; 128: 97-105.
43. Silben PL, Leong LL, Sturm MJ, Strophair J, Taylor RR. Short-term vitamin E supplementation has no effect on platelet function, plasma phospholipase A2 and lyso-PAF in male volunteers. Clin Exp Pharmacol Physiol 1990; 17: 645-51.
44. 1 and vitamin E in serum. Clin Chem 1989; 35: 2285-9.
45. Halliwell B. The role of oxygen radicals in human disease, with particular reference to the vascular system. Haemostasis 1993; 23 (suppl. 1): 118-26.
46. Frick MH, Elo O, Happa K et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. N Engl J Med 1987; 317: 237-45.